Home>Topics>Stocks>Dendreon Corporation

Dendreon Corporation

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
  1. Dendreon Ready For A Rebound


    Tue, 25 Mar 2014

    license single therapies to these winners should also do well. Dendreon ( DNDN ) has an immunotherapy for prostate cancer already commercialized ..... has done poorly as the company continues to generate losses. DNDN is cheaper per share today than it was in 2006 when Complete

  2. 3 Reasons To Buy Dendreon


    Mon, 24 Mar 2014

    By Renu Singh : Biotechnology company Dendreon 's ( DNDN ) performance this year hasn't been ..... This doesn't come as a surprise since Dendreon 's recent fourth-quarter results were ..... prior fiscal period, signifying that Dendreon is making progress, even though it didn

  3. Dendreon's CEO Presents at Cowen and Company 34th Annual Health Care Conference (Transcript)


    Tue, 4 Mar 2014

    Dendreon Corp. ( DNDN ) Cowen and Company 34th Annual Health ..... by John Johnson, Chairman and CEO of Dendreon and looking forward to his updates ..... I may make today. So if you look at Dendreon , yesterday we announced our fourth

  4. Dendreon : The Time Is Now


    Tue, 18 Feb 2014

    this quarter than for biotech darling Dendreon ( DNDN ). The name that brings you the prostate ..... announce), investors need to prepare. Dendreon has a number of questions to answer ..... quarter of 2013: About a month ago, Dendreon pre-announced some of its fourth quarter

  5. New Morningstar Analyst Report for Seattle Genetics, Inc.

    Stock Reports

    Fri, 17 Jan 2014

    in the investment community (given the recent failure of Dendreon 's pricey prostate cancer drug to live up to sales expectations ..... in the investment community following the recent failure of Dendreon 's DNDN pricey prostate cancer drug Provenge to live up to sales expectations

  6. If Northwest Biotherapeutics Wins, It Wins Big


    Mon, 2 Dec 2013

    for solid tumors will finally reach the market. The cancer vaccine is a pretty new therapeutic area, and so far, only Dendreon ( DNDN )'s Provenge for prostate cancer and Bristol Myer Squibb ( BMY )'s Yervoy for skin cancer have gained the FDA approval

  7. Dendreon Receives Positive EU Opinion for Provenge; No Change to Fair Value Estimate or Moat Rating


    Fri, 28 Jun 2013

    Dendreon DNDN announced that it received a positive ..... Commission later this year, and we expect Dendreon to announce its commercialization plans ..... rating intact as we remain concerned about Dendreon 's ability to achieve meaningful commercial

  8. Provenge Sales Plummet in Dendreon's First Quarter


    Thu, 9 May 2013

    Dendreon DNDN reported dismal first-quarter results ..... prostate cancer space. Though we believe Dendreon 's first quarter will be a low-water ..... product revenue in the third quarter. Dendreon had $337.3 million in cash and investments

  9. Account Growth and Lower Costs Are Bright Spots in Dendreon's Third Quarter


    Fri, 2 Nov 2012

    deluge of negative developments over the last two years, Dendreon DNDN investors may finally be getting some good news in the firm ..... sequential basis. Despite continued slow Provenge sales traction, Dendreon 's cost-cutting efforts are beginning to take hold. The

  10. Cramer's Lightning Round - Dendreon Has A Cloudy Future In A Crowded Place (9/10/12)


    Tue, 11 Sep 2012

    Mart ( WMT ) : "That last quarter wasn't good ... wait for it to drop to $71 and pull the trigger." Bearish Calls: Dendreon ( DNDN ): "No, no, no. A very cloudy future in a very crowded place." Southwestern Energy ( SWN ) : "It's cheap, but

« Prev1234Next »
Content Partners